MedTrace Logo

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

NCT03485547 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2026-02-02

No results posted yet for this study

Summary

This research study is studying a drug as a possible treatment for BPDCN.

The intervention involved in this study is: Venetoclax

Conditions

  • Blastic Plasmacytoid Dendritic Cell Neoplasm

Interventions

DRUG

Venetoclax

VENCLEXTA targets BCL-2 in order to help restore the process of apoptosis. Through apoptosis, your body allows cancer cells and normal cells to self-destruct

Sponsors & Collaborators

Principal Investigators

  • Andrew Lane, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-23
Primary Completion
2022-01-10
Completion
2025-04-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03485547 on ClinicalTrials.gov